Henry Meds

• Multi-month bundle discount
• Personalized dosing tier

What Henry Meds actually is

Henry Meds is one of the largest private 503A-pathway telehealth compounders in the US. The model is structurally similar to Hims & Hers (covered in our Hims audit) but private rather than publicly traded - operationally mature, multi-vertical (GLP-1 weight management, women's HRT, testosterone, ED, phentermine), with broad state coverage through an affiliated dispensing pharmacy network.

The brand-level positioning is the "no insurance, no waiting rooms" cash-pay frame. Pricing is published directly on the site rather than gated behind a quote flow, and the monthly cadence is simpler than the Hims subscription ladder. That posture is the audit's headline buyer-experience signal.

The audit-tier question is structurally the same one that applies to the entire post-shortage cohort: how the "personalized" compounding pathway holds up under FDA scrutiny.

Why the regulatory frame is the same as Hims

The single most important fact about every 503A compounded-GLP-1 vendor right now is that the FDA's shortage-status discretion ended in 2025 for both semaglutide and tirzepatide. The legal pathway narrowed from "shortage exception" (under which most telehealth compounders entered the market in 2023-2024) to the "clinical-need personalization" exception - the pharmacy compounds only because a specific patient cannot use the commercially-available drug for a specific clinical reason.

Henry Meds operates under the same personalization-pathway framework as Hims. The FDA's public position applies equally: personalization must be tied to documented clinical need, not used as a marketing pathway to preserve the shortage-era business model. The regulatory cloud over Henry Meds is therefore the same as the cloud over Hims, even though no Henry-Meds-specific FDA action has surfaced in our public-record pass.

We covered the broader regulatory backdrop in 503A and the PCAC: how compounding restrictions closed the legal GLP-1 market and compounded semaglutide in 2026: where the legal channel actually stands.

Where Henry Meds scores differently from Hims

The composite rating sits at 6.2/10, slightly above the Hims 6.0. The difference is concentrated in two dimensions.

Buyer experience (7.0 vs Hims 5.5). Trustpilot signal is roughly one full point higher than Hims (4.6 vs 3.8) across a comparable review volume (~9,500 reviews). Recurring positive themes are the cash-pay simplicity, the lack of insurance-related claim friction, and the multi-vertical platform that lets a household consolidate HRT + weight-management on one account.

Public dispute risk lower (FDA history same, but no Novo Nordisk public-dispute drag). The Hims-Novo Nordisk partnership termination in mid-2025 was the most visible brand-manufacturer / telehealth-platform dispute in the GLP-1 space and it drags the Hims FDA-history dimension. Henry Meds has not had an equivalent public dispute, so the FDA-history score doesn't pick up the additional Hims-specific drag.

Other dimensions track Hims closely because the structural model is identical: affiliated dispensing pharmacy network, per-fill pharmacy not disclosed at checkout, API sourcing not disclosed publicly, named prescriber identity not surfaced on the site.

What buyers consistently report

Across roughly 9,500 Trustpilot reviews, Henry Meds carries a rating in the 4.5-4.7 band. The volume is mature enough for the rating to be statistically reliable. Recurring positive themes are checkout simplicity, broad state coverage, and the platform-level reliability you'd expect from a multi-million-customer telehealth operator. Recurring negative themes are subscription-cancellation friction, mixed product quality at the fill level (common across the cohort, not specific to Henry Meds), and a perception that customer-support escalation is slower than at smaller compounders.

The May 2026 monthly survey on r/Tirzepatidecompound placed Henry Meds in the mid-tier alongside Hims rather than in tier-1 (which was Trillium) or tier-2 (which was Fifty410). The community consensus reads similar shape to the Trustpilot signal: operationally reliable, regulatory cloud held in common with Hims.

The structural caveat on buyer-experience signal is the same as for every other entry in our v0 cohort. Buyer satisfaction measures the platform's UX, not the compounding pharmacy's sterility practice. A 4.6 Trustpilot score and a clean (or unclean) FDA record at the affiliated dispensing pharmacy are measuring different things.

What's missing from public records

This audit is the public-data tier. To upgrade Henry Meds to a full audit tier we would need:

• A first-hand consult and fill placed by the vialaudit desk, with the affiliated dispensing pharmacy identified pre-purchase if available, or documented as undisclosed if not
• The named-prescriber identity and NPI number tied to the fill, with state-medical-board cross-checks for the state the fill ships to
• Per-state non-resident pharmacy license verification for each affiliated dispensing facility, pulled directly from each state's Board of Pharmacy database
• The Henry Meds written refund and cancellation policy as published, archived against any future quiet revisions
• A third-party lab test on the actual fill, against label claim for identity and purity (HPLC + mass spec)
• A snapshot of any pending or recent FDA correspondence with the affiliated dispensing pharmacies. As a private company, Henry Meds does not have a SEC-disclosure equivalent for FDA correspondence outside the public FDA inspection database

We have not done that work yet. This profile reflects what is verifiable from public records as of the last-audited date.

Editorial note - private-company audit is structurally thinner than public

This profile is the fourth in the v0 compounding-pharmacy vertical, after Trillium, Fifty410, and Hims. The Hims audit benefited from a public-company disclosure regime that surfaced SEC filings, shareholder litigation, and the Novo Nordisk dispute into the verifiable record. Henry Meds is private. The audit reads the same FDA framework but with thinner per-company evidence outside the platform itself.

A buyer optimizing for cash-pay simplicity and a strong buyer-experience signal has reasons to choose Henry Meds that this audit does not contradict. A buyer optimizing for the lowest prospective regulatory risk on the actual fill should read the FDA's public statements on the personalization pathway carefully before committing to any post-shortage 503A compounded GLP-1, Henry Meds included.

See /methodology/compounding for the rubric weights that produce this score and the conflict-of-interest constraints that govern this desk.

• Henry Meds homepage↗ — vendor
• Henry Meds weight-management program↗ — vendor
• FDA - Compounding under section 503A of the Federal Food, Drug, and Cosmetic Act↗ — FDA
• FDA - Compounding inspections, recalls, and other actions↗ — FDA
• Henry Meds - Trustpilot profile↗ — Trustpilot
• r/tirzepatidecompound May 2026 telehealth & pharmacy survey↗ — Reddit community survey
• vialaudit - Compounded semaglutide in 2026 status read↗ — vialaudit
• vialaudit - 503A and the PCAC GLP-1 compounding article↗ — vialaudit